Literature DB >> 22424126

Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis.

Renzo Mancuso1, Sara Oliván, Pilar Mancera, Andrea Pastén-Zamorano, Raquel Manzano, Caty Casas, Rosario Osta, Xavier Navarro.   

Abstract

Knowledge of the potential effect of genetic background in disease models is important. The SOD1-G93A transgenic mouse is the most widely used model in amyotrophic lateral sclerosis (ALS). Since these animals show considerable variability both in the onset and the progression of the disease, this study aimed to characterize the potential differences between the two most widely used strains, C56BL/6 (B6) and B6SJL. A rotarod test was carried out to assess strength and motor coordination, while electrophysiology tests were performed to evaluate the function of upper and lower motor neurons. Survival of the animals and motor neuron loss were also studied. The results did not show any background effect regarding the rotarod test, despite the differences in the pattern of decline in central and peripheral motor conduction. The onset of motor neuron abnormalities was later in B6SJL mice, but progressed more rapidly. Lifespan was longer for B6 than for B6SJL animals. In conclusion, background differences in disease onset and progression are important. The characteristics of the strain should be taken into account in experimental design of therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424126     DOI: 10.3109/17482968.2012.662688

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  22 in total

1.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

2.  Oxidative stress and autophagic alteration in brainstem of SOD1-G93A mouse model of ALS.

Authors:  Ting An; Pengxiao Shi; Weisong Duan; Shipan Zhang; Pin Yuan; Zhongyao Li; Dongxia Wu; Zuoshang Xu; Chunyan Li; Yansu Guo
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

3.  Sigma-1R agonist improves motor function and motoneuron survival in ALS mice.

Authors:  Renzo Mancuso; Sara Oliván; Amaya Rando; Caty Casas; Rosario Osta; Xavier Navarro
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  Specific Expression of Glial-Derived Neurotrophic Factor in Muscles as Gene Therapy Strategy for Amyotrophic Lateral Sclerosis.

Authors:  Guillem Mòdol-Caballero; Mireia Herrando-Grabulosa; Belén García-Lareu; Sergi Verdés; Rubén López-Vales; Gemma Pagès; Miguel Chillón; Xavier Navarro; Assumpció Bosch
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

5.  EST79232 and EST79376, Two Novel Sigma-1 Receptor Ligands, Exert Neuroprotection on Models of Motoneuron Degeneration.

Authors:  Núria Gaja-Capdevila; Neus Hernández; Sandra Yeste; Raquel F Reinoso; Javier Burgueño; Ana Montero; Manuel Merlos; José M Vela; Mireia Herrando-Grabulosa; Xavier Navarro
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

6.  Neurite orientation dispersion and density imaging can detect presymptomatic axonal degeneration in the spinal cord of ALS mice.

Authors:  R G Gatto; S M Mustafi; M Y Amin; T H Mareci; Yu-Chien Wu; R L Magin
Journal:  Funct Neurol       Date:  2018 Jul/Sept

7.  Upregulation of Vesicular Glutamate Transporter 2 and STAT3 Activation in the Spinal Cord of Mice Receiving 3,3'-Iminodipropionitrile.

Authors:  Tomohiro Ohgomori; Ryo Yamasaki; Jun-Ichi Kira; Shozo Jinno
Journal:  Neurotox Res       Date:  2017-09-30       Impact factor: 3.911

8.  Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis.

Authors:  Maria A Lim; Kendra K Bence; Ishani Sandesara; Pénélope Andreux; Johan Auwerx; Jeff Ishibashi; Patrick Seale; Robert G Kalb
Journal:  Hum Mol Genet       Date:  2014-05-15       Impact factor: 6.150

9.  Optimizing mouse models of neurodegenerative disorders: are therapeutics in sight?

Authors:  Cathleen M Lutz; Melissa A Osborne
Journal:  Future Neurol       Date:  2013-12-16

10.  Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis.

Authors:  Guillem Mòdol-Caballero; Belén García-Lareu; Sergi Verdés; Lorena Ariza; Irene Sánchez-Brualla; Frédéric Brocard; Assumpció Bosch; Xavier Navarro; Mireia Herrando-Grabulosa
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.